TT 034
Alternative Names: TT-034Latest Information Update: 27 May 2021
At a glance
- Originator Benitec Biopharma
- Developer Tacere Therapeutics
- Class Antivirals; Small interfering RNA
- Mechanism of Action Hepatitis C virus replication inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 24 Sep 2018 Tacere Therapeutics terminated a phase I/II follow-up trial for Hepatitis C in USA (NCT02315638)
- 30 Nov 2016 Tacere Therapeutics completes a phase I/II trial in Hepatitis C in USA (NCT01899092)
- 26 Feb 2016 Discontinued - Phase-I/II for Hepatitis C in USA (IV)